HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics

More filters

Study design
Intervention type
Study phase

Recruiting now refers to the overall study. Local openings are shown only when the registry lists an open site.

1725studies shown
Showing 97-108 of 1,725
Drug study icon
RecruitingNCT07105111

Valbenazine for ongoing tardive dyskinesia symptoms

About this titleRead the official source — NCT07105111
Official study title

A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Recruiting in the United States
Schizophrenia, Depression, ...Medication studyAges 18+
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
RecruitingNCT07140913

KarXT with lithium, valproate, or lamotrigine for mania in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Read the official source — NCT07140913
What is this study about?

Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, France, Argentina, + 10 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06951698

KarXT for manic episodes in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Read the official source — NCT06951698
What is this study about?

Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, Australia, New Zealand, + 6 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06951711

KarXT for mania in bipolarity: BALSAM-2 study

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Read the official source — NCT06951711
What is this study about?

Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, China, Croatia, + 8 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT07424404

Long-term safety of xanomeline and trospium in children and adolescents

About this titleRead the official source — NCT07424404
Official study title

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride in Children and Adolescents With Psychiatric Disorders

Recruiting in the United States
SchizophreniaMedication studyAges 5–17
Countries
United States, Australia, France, + 7 others
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.